tirzepatide egfr Effects of on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial Tirzepatide and Cardiovascular Outcomes: A
Description
hematoma, pseudoaneurysm) are the most common complications following PVI and occur in approximately 1-4% (KD: I think complication rate is lower in studies Ive reviewed) cases
Originally approved by the FDA for managing type 2 diabetes, Tirzepatide quickly gained recognition for its powerful weight loss effects
DOI:10.1080/17461391.2022.2040597 J Zapata, A Gallardo et al
Do not restart tirzepatide if pancreatitis is confirmed unless an alternative etiology is clearly identified
[DOI] [PMC free article] [PubMed] [Google Scholar] 16.Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ
